Genomewide association study of epiretinal membrane: discovery of significant risk loci in each of three American populations Short title: GWAS of Epiretinal Membrane in Multiple Populations Joel Gelernter (1,2,3, *), Daniel Levey (1,2), Marco Galimberti (1,2), Kelly Harrington (4,5), Hang Zhou (1,2), Keyrun Adhikari (1,2), J. Michael Gaziano (6,7), Dean Eliott (8), and Murray B. Stein (9,10) 1. Department of Psychiatry, Yale School of Medicine, New Haven, CT. 2. Department of Psychiatry, VA Connecticut Healthcare Center, West Haven, CT. 3. Departments of Genetics and Neuroscience, Yale School of Medicine, New Haven, CT. 4. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA. 5. Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, , Boston, MA. 6. Department of Medicine, Harvard Medical School, Boston, MA. 7. Department of Medicine, Divisions of Aging and Preventative Medicine, Brigham and Women's Hospital, Boston, MA. 8. Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA. 9. University of California, San Diego, La Jolla, CA. 10. VA San Diego Healthcare System, San Diego, CA. *Correspondence Joel Gelernter, Department of Psychiatry, **Division of Human Genetics** Yale University School of Medicine, VA CT Healthcare Center West Haven, CT 06516. joel.gelernter@yale.edu.

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Abstract **IMPORTANCE**: Epiretinal membrane (ERM) is a common retinal condition characterized by the presence of fibrocellular tissue on the retinal surface, often with consequent loss of vision and visual distortion. **OBJECTIVE**: Genomewide association studies (GWAS) can reveal the biology underlying complex genetic traits like ERM; there have been no previous large-scale GWAS of this trait. **DESIGN:** We used electronic health record diagnosis to identify Million Veteran Program (MVP) participants with ERM in three populations for genomewide association analysis and further statistical investigation of the results. **SETTING:** Veterans who volunteered for the nationwide Department of Veterans Affairs MVP study, eligible because they have used Veterans Health Administration facilities PARTICIPANTS: 31,374 European-American (EUR) cases and 414,052 EUR controls, 4,739 African-American (AFR) cases and 107,773 AFR controls, and 2,119 Latino (Admixed American, AMR) cases and 36,163 AMR controls – a total of 38,232 cases and 557,988 controls. METHODS: We completed GWAS in each population separately, then results were meta-analyzed. We also evaluated genetic correlation with other traits in external samples, and completed pathway enrichment analyses. MAIN OUTCOME MEASURES: Genomewide-significant association with ERM. **RESULTS:** Genomewide significant associations were observed in all three populations studied: 31 risk loci in EUR subjects, 3 in AFR, and 2 in AMR, with 48 identified in trans-ancestry meta-analysis. The most strongly associated locus in both EUR (rs9823832, p=9.06x10⁻³⁷) and the meta-analysis (rs28630834, p=2.90x10⁻³⁷) was DHX36 (DEAH-Box Helicase 36). We investigated expression quantitative trait locus associations for eye related function and found several GWS variants associate to alterations in gene expression in the macula, including DHX36*rs9438. ERM showed significant genetic correlation to

depression and to disorders of the vitreous. Pathway enrichment analyses implicated collagen and collagen-adjacent mechanisms, among others.

CONCLUSIONS AND RELEVANCE: This well-powered ERM GWAS has identified novel genetic associations, some very strong, that point to biological mechanisms for ERM and merit further investigation.

Keywords: Million Veteran Program (MVP), genomewide association study (GWAS), epiretinal membrane (ERM), macular pucker, multi-ancestry study, transcriptome wide association study (TWAS), pleiotropy

Introduction

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

Epiretinal membrane (ERM), sometimes called macular pucker, is characterized by the proliferation of cells on the retinal surface. These cells adhere to the retina, produce extracellular matrix, and develop contractile properties, resulting in tangential retinal traction and distortion of the retinal architecture. Symptoms can be severe and require surgery; patients may complain of loss of central vision and/or visual distortion (metamorphopsia, "wavy vision"). Diagnosis can be established by ophthalmoscopy, fundus photography, and optical coherence tomography (OCT). It is common, with prevalence of 2% in patients age >50 and 20% age >75. Age is associated with increased risk, and smoking may be associated with decreased risk¹. The most common cause is posterior vitreous detachment, an age-related separation of the vitreous from the retina. Most patients do not require intervention; for those with symptomatic ERM, vitrectomy with epiretinal membrane peeling is the typical treatment and results are variable; there is no nonsurgical treatment. While many of the pathophysiological processes that lead to ERM are known and there is considerable knowledge of its biology², the underlying molecular genetic risk factors are not understood. Genomewide association studies (GWAS) are presently the most useful, and most universally applicable, tools to understand the biology underlying genetically complex traits such as ERM. Large GWAS have been previously performed to identify common variant associations with defects related to the macula, but these have focused mostly on age-related macular degeneration (AMD)³ (including the first major GWAS⁴.) A GWAS study in the UK Biobank considered AMD, diabetic retinopathy, retinal detachment, glaucoma, and myopia, with risk loci mapped for each trait and pleiotropy between them⁵. A large GWAS of cataract in UK Biobank⁶, Genetic Epidemiology Research on Adult Health and Aging (GERA)⁷, and 23 and me (a personal genomics company) reported 54 genomewide significant (GWS) risk loci. ERM,

though, has, to our knowledge, not been studied with respect to genetics using any genomewide approach.

To identify a large number of risk genes, novel biology, and phenotypic subtypes, GWAS with large sample size are necessary. The Department of Veterans Affairs (VA) Million Veteran Program (MVP) is one of the world's largest biobanks including genetic, environmental, and medical information, based on data from United States military veterans. ⁸⁻¹¹. The MVP has enrolled >900,000 participants, with excellent representation from non-European-ancestry participants. Genotype data are currently available for >650,000 participants. The MVP sample is relatively old (55% are between ages 50-69¹⁰) and ill – subjects are enrolled based on their use of the US Veterans Health Administration system. We conducted a GWAS of ERM in the MVP sample, using diagnoses based on the electronic health record (EHR).

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Subjects and Methods **MVP**: Primary analyses We used data release version 4 of the MVP. 12 Linked and de-identified EHRs were queried using the Veterans Affairs Informatics and Computing Infrastructure to identify individuals with International Classification of Disease (ICD) codes for ERM, specified in the Supplementary Methods. These codes identified 31,374 European-American (EUR) cases and 414,052 EUR controls, 4,739 African-American (AFR) cases and 107,773 AFR controls, and 2,119 AMR (Admixed American or Latino) cases and 36,163 AMR controls; more detail is provided in Table 1. Research involving the MVP in general is approved by the VA Central Institutional Review Board. All participants provided written informed consent. FinnGen: Phenotypes for pleiotropy analyses We accessed GWAS summary statistics from FinnGen¹³, a Finnish nationwide biobank collection, data freeze version 7, for two traits potentially relating to ERM, "diseases of the vitreous body" and "glaucoma". ICD-10 codes used for diagnosis definition, Supplementary Methods. Genotyping, Imputation, Quality Control (QC), and GWAS Genotyping and imputation of MVP subjects has been described previously. 10,14 Briefly, a customized Affymetrix Axiom Array was used for genotyping. MVP genotype data for biallelic SNPs were imputed using Minimac4 and a reference panel from the African Genome Resources (AGR) by the Sanger Institute. Details, Supplement. For the FinnGen dataset¹³, results were downloaded from the FinnGen website after registration (https://www.finngen.fi/en/access results). Analyses details are given in the Supplement.

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

Heritability and Genetic correlations Linkage disequilibrium score regression (LDSC)¹⁵ was used to calculate liability scale SNP-heritability for EUR, AFR and AMR ancestry of MVP data for ERM. We used a value of 0.091 for the population prevalence ¹. For EUR, this was calculated directly with LDSC. To estimate liability scale SNP-heritability for AFR and AMR cohorts, we calculated LD scores with cov-LDSC ¹⁶ from 10,000 random independent individuals for the SNPs identified in the HapMap Project ¹⁷. LDSC was also used to calculate genetic correlation¹⁸ between the EUR MVP data for ERM and four other traits: two ophthalmologic traits, glaucoma¹⁹ and disorders of the vitreous body¹³; and two psychiatric traits, posttraumatic stress disorder (PTSD)²⁰ and depression²¹. Cross-ancestry Fine-mapping We did fine-mapping leveraging LD information from multiple ancestries to identify potential causal variants using MsCAVIAR²². Details, Supplement. Expression QTLs (eQTL) GWAS significant loci were investigated to determine whether they were eQTLs using an eye tissue specific database ²³. Lead variants from the EUR ancestry GWAS were looked up first; if lead variants were not available proxy SNPs were selected from genomewide significant (GWS) variants in the same locus. Transcriptome-Wide Association Study (TWAS) and Fine-mapping We performed TWAS using FUSION²⁴ for the EUR GWAS statistics. Details, Supplement.

MAGMA gene-based and gene set analyses

We used MAGMA ²⁵ implemented in FUMA ²⁶ for gene-based and gene-set analyses. Details,

Supplement.

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

Results MVP analyses GWS associations were observed in all three populations studied. 31 risk loci were identified in EUR subjects, 3 in AFR, and 2 in AMR, reflecting the greater power of the analysis in EUR compared to the other two populations presumably due to difference in sample sizes (Table 2a-c; Figures S1-S3). In EUR, of the 31 GWS loci, 14 were associated with a p-value <10⁻¹⁰. The most strongly supported variant was rs9823832 (p=9.06x10⁻³⁷) which maps to *DHX36* (DEAH-Box Helicase 36). Other associated variants highlighted for biological interest (Discussion) include CPLX4 (rs7244528 associated at 2.84x10⁻¹ ²²), ROBO3, to which variant rs10893291 maps (associated at 6.12x10⁻¹⁷), and rs1011400 at locus ABLIM3 $(p=2.87x10^{-14})$. Additional associated loci include FTO*rs17817964 $(p=3.04x10^{-11})$ (FTO Alpha-Ketoglutarate Dependent Dioxygenase) and RARB*rs57281891 (p=1.13x10⁻¹⁰) (Retinoic Acid Receptor Beta). Other associated variants map to CDKN2B-AS1 (rs10120688, p=8.35x10-19) and ACOXL – two independent variants >115,000 basepairs apart, rs6731210 (p= 5.93×10^{-18}) and rs114671763 (p= 1.13×10^{-18}) ¹¹). In AMR, the most strongly associated locus (p=2.21x10⁻⁹) was CHRM2*rs7801770, which encodes Cholinergic Receptor Muscarinic 2. (This CHRM2 SNP is not polymorphic in EUR and non-significant in AFR (p=0.44).) The trans-ancestry meta-analysis identified 48 GWS variants (Figure 1, Table 3); many were not significant (at p≤5x10⁻⁸) in any of the population-specific analyses. Of these 48 variants, 27 regions had p-value stronger than 10^{-10} . In numerous cases, the same gene was implicated in the meta-analysis as for EUR but with a different lead variant; the same variant as for EUR-only and meta-analysis was implicated in 15 instances (Table 3). In the trans-ancestry meta-analysis, the most strongly supported variant maps to DHX36 as for EUR – a different variant at the same risk locus, rs28630834 (p= 2.90×10^{-37}).

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

The only variant that was GWS in more than one population was RNU6ATAC21P*rs34825161 (RNA, U6atac Small Nuclear 21, Pseudogene), significant in EUR (p=2.15x10⁻¹⁸), AFR (p=1.84x10⁻⁸), and also the trans-ancestry meta (p=3.88x10⁻²⁴). The other variants identified in AFR and AMR may be populationspecific. Heritability and Genetic correlations The LDSC analysis showed significant heritability for EUR ERM ($h^2=0.050\pm0.006$; p=3.41×10⁻¹⁵) and demonstrated significant positive genetic correlation (r_g) between ERM and disorders of the vitreous body $(r_e=0.25\pm0.087; p=0.39\times10^{-2})$, and depression $(r_e=0.14\pm0.039; p=0.04\times10^{-2})$, whereas the genetic correlations between ERM and glaucoma and PTSD were not significant (rg=0.007±0.063, p=0.92; r_{σ} =0.080±0.057; p=0.16). The Manhattan plot for the GWAS on "disorders of the vitreous body" is provided in Figure S4. We also observed significant heritability in AFR (h²=0.064±0.031; p=0.039) but we obtained a non-significant heritability for AMR (h²=0.021±0.050; p=0.67). Due to lack of power and comparators, it was not possible to examine genetic correlations in these latter two populations. <u>Cross-ancestry Fine-mapping for potential causal variants</u> We performed fine-mapping to identify potential causal variants in 33 loci identified by the crossancestry meta-analysis (Table S1). The median number of SNPs in the credible sets was 7. Six credible sets contain only a single variant with PIP ≥99% which could be targets for follow-up studies, including rs114671763, rs34825161, rs76152172, rs6477779, rs8094635 and rs117896793. There are 18 credible sets with ≤5 variants. Associated variants' influence on gene expression

218

219

220

221

222

223

224

225

226

227

228

229230231232

233

234

235

236

237

238

239

240

241

242

Two lead variants from the EUR GWAS were significantly associated with gene expression changes in the eye, rs1011400 and rs4245808 (Figure 2). Rs1011400 was significantly associated with changes in antisense RNA transcript AC012613.2 in both macula (p=5.43x10⁻¹⁶, FDR=2.78x10⁻¹²) and non-macula retinal tissue (p=6.48x10⁻¹², FDR=1.75x10⁻⁸). Rs1011400 was also significantly associated with changes in macula ABLIM3 (p=1.22x10⁻⁴, FDR=0.036) expression. Rs4245808 was significantly associated with nonmacular retinal pigment epithelium expression of AC073283.1 (p=2.86x10⁻⁵, FDR=0.017). Three additional GWS proxy variants were associated with eye gene expression changes: rs2416908 (proxy for rs4838069) was associated with expression changes in DENND1A (the gene encoding DENN Domain Containing 1A) in macular retinal pigment epithelium (p=6.24x10⁻⁵, FDR=0.036), rs803141 (proxy for rs2277066) with CCNI2 (encoding Cyclin I Family Member 2; p=1.14x10⁻⁸, FDR=2.26x10⁻⁵) and SEPT8 (encoding Septin 8; p=3.00x10⁻⁵, FDR=0.018) in non-macular retinal pigment epithelium, and rs9438 (proxy for rs9823832) with *DHX36* in the macula ($p=2.80x10^{-5}$, FDR=0.011). Transcriptome-Wide Association Study (TWAS) and Fine-mapping TWAS identified 28 independent associated genes (Table S2). The most significant gene was DDX50P2 in testis (p= 0.92×10^{-24}), a pseudogene, followed by CDKN2A (p= 0.29×10^{-17}) in the brain cortex. For TWAS fine-mapping, we obtained 12 genes with posterior inclusion probability (PIP) \geq 0.9, and 7 more genes with PIP ≥ 0.7 (Table S3). Four genes had the highest PIP value (PIP=1): CRIPT, MUSK, DDX50P2, and MALT1. MAGMA gene-based and gene set analyses MAGMA gene-based analysis provided a list of 25 significant genes which survived Bonferroni correction (p<2.62x10⁻⁶); these were provided as input for the gene set enrichment analysis (Table S4).

We obtained one significant term, the curated gene set of vitamin C in brain (Beta=1.296, STD=0.027, SE=0.282, p=2.12×10⁻⁶, P_{bon}=0.033).

Functional Enrichment Analysis

There were significant enrichment results with six GO pathways (cyclin-dependent protein serine/threonine kinase inhibitor activity, collagen type IV trimer, networking-forming collagen trimer, collagen network, basement membrane collagen trimer, and complex of collagen trimers), and two significant protein complexes (CycD–Cdk4 and IL4-IL4R) (Table S4).

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

Discussion In this first well-powered GWAS of ERM conducted in the MVP, we identified 31 independent GWS risk loci in EUR participants, 3 independent loci in AFR, and 2 in AMR. In the trans-ancestry meta-analysis, 48 independent risk loci were identified. This trait is very important clinically – it is the most common retinal disease in adults²⁷ -- and it causes substantial morbidity. The most strongly supported variant in EUR was rs9823832 (p=9.06x10⁻³⁷), at DHX36 (DEAH-Box Helicase 36). In the trans-ancestry meta-analysis, the most strongly supported variant also maps to DHX36 – a different variant at the same locus, rs28630834 (p=2.90x10⁻³⁷). We did not identify any previous association of this locus to an ocular phenotype, but its relevance is supported by follow-up analysis that found that a GWS SNP in this locus (rs9438, p=6.38x10⁻¹³) alters expression of *DHX36* in macula (Figure 2). Considering some of the other associated variants of immediate biological interest in EUR, the protein product of *CPLX4* (rs7244528, p=2.84x10⁻²²) plays a role in photoreceptor ribbon synapses^{28,29}. ROBO3, to which variant rs10893291 maps (p=6.12x10⁻¹⁷), encodes Roundabout Guidance Receptor 3, involved in axonal navigation³⁰. Rs1011400 maps to ABLIM3 (p=2.87x10⁻¹⁴), which encodes an actinbinding protein related to nervous system development, previously reported to be associated to macular thickness³¹. We noted that variation at this locus alters expression in the macula of ABLIM3 and AC012613.2. FTO*rs17817964 (p=3.04x10⁻¹¹) represents a locus well known for associations to body mass index-related traits. RARB*rs57281891 (p=1.13x10⁻¹⁰) maps to the locus that encodes Retinoic Acid Receptor Beta, which binds retinoic acid. This locus has been previously associated to optic disc area³². Rs10120688 (CDKN2B-AS1) has been associated to primary open-angle glaucoma (POAG)³³. LPAR1, the second-most-strongly associated locus both in EUR (p=1.81x10⁻²⁶) and in the trans-ancestry metaanalysis (p=2.34x10⁻²⁶) (different SNPs) encodes lysophosphatidic acid receptor 1. The protein product is

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

a G-protein coupled receptor with a range of biological functions implicated in several traits with variants associated to eosinophil count³⁴, and central corneal thickness³⁵. Other associated variants are linked to a range of different biological functions, e.g. two independent variants map to ACOXL (Acyl-Coenzyme A Oxidase-Like Protein), (rs6731210, p=5.93x10⁻¹⁸; rs114671763, p=1.13x10⁻¹¹; fine-mapping revealed it is a potential causal variant with PIP >0.99) – this locus was previously associated to chronic lymphocytic leukemia³⁶. In AMR, the most strongly associated locus (p=2.21x10⁻⁹) was CHRM2, which encodes Cholinergic Receptor Muscarinic 2. Atropine, a mydriatic, is an agonist at the protein product of CHRM2, as is carbamoylcholine, an anti-glaucoma agent. Different variants at this locus have been shown to be associated to resting heart rate response to recovery after exercise³⁷ and to risk-taking behavior³⁸, among other phenotypes. Considering the association with ERM and CHRM2 observed in AMR as well as CDKN2B-AS1 (previously POAG-associated) in EUR, we explored the relationship of ERM and glaucoma further, but the genetic correlation between ERM and glaucoma was not significant; clinically, these traits (ERM and glaucoma) are not considered to be associated. LDSC was feasible only in EUR, and it is possible that this lack of a significant genetic correlation between these traits reflects an AMR-specific genetic relationship -- the lead CHRM2 variant was monomorphic in EUR and not significant in AFR. However, there were significant genetic correlations between ERM and two other traits evaluated, depression and disorders of the vitreous (the latter from a FinnGen analysis). Visual impairment has been reported previously to be associated with increases in depression ^{39,40}. ERM is related to vitreous pathology, and risk is increased by vitreous detachment²⁷.

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

The trans-ancestry meta-analysis identified 48 GWS variants, many not observed in any of the population-specific analyses. In numerous cases, the same gene was implicated but with a different lead variant, supporting shared biology between populations (Table 3). The only variant that was GWS in more than one population was RNU6ATAC21P*rs34825161 (RNA, U6atac Small Nuclear 21, Pseudogene), significant in EUR, AFR, and the trans-ancestry meta-analysis. The other variants identified in AFR and AMR were not GWS in the meta-analysis, and these associations may be population-specific. CRIPT, one of the genes identified by TWAS, encodes the Cysteine-Rich PDZ-Binding Protein, and high myopia is among several clinical traits associated with variants at this locus in a patient with an exon 1 deletion⁴¹. Another TWAS-associated gene, CDKN2B-AS1, which encodes Cyclin Dependent Kinase Inhibitor 2A, is associated with POAG, as noted above, and with several melanoma subtypes⁴². The protein product of MUSK, Muscle Associated Receptor Tyrosine Kinase, has been implicated in clustering of postsynaptic acetylcholine receptors in neuromuscular junction⁴³ – interesting in the context of the CHRM2 (Cholinergic Receptor Muscarinic 2) SNP-based association discussed above. Pathway enrichment analysis using two different approaches revealed significant findings for collagen and for the collagen-adjacent vitamin C pathway. Vitamin C (ascorbic acid) is necessary for the hydroxylation of the proline residue in collagen, necessary to stabilize collagen fibers 44; MAGMA gene set enrichment analysis implicated vitamin C brain pathways. Collagen is a major constituent of epiretinal membranes, varying depending on the kind of membrane⁴⁵ and a proteomic study has demonstrated that some collagens are upregulated in ERM⁴⁶. Collagen type I and type IV are the two primary collagens founded in corneal and lens tissues; ⁴⁷ g:profiler implicated collagen type IV trimer, network-forming collagen trimer, collagen network, basement membrane collagen trimer, and complex of collagen trimer (Table S4).

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

Above we highlight biology mostly consistent with prior knowledge, but our results also implicate more peripherally-connected biology. FOXL1, for example, encodes forkhead box L1. The same variant at this locus (rs1019574) is strongly associated to ERM in both EUR and the trans-population meta-analysis. Prior associations at this locus relate to, for example, bone mineral density⁴⁸ and height⁴⁹. It is also involved in eye development⁵⁰, but may implicate a novel mechanism in the context of ERM. Non-European populations are generally understudied with respect to GWAS. Since many genetic findings are at least to some extent population-specific, this is a major limitation that needs to be addressed by the research field as a whole⁵¹. For personalized medicine to become an effective strategy, population-specific polygenic risk scores will generally need to be available for each clinical population where a need for risk prediction is anticipated. This study demonstrates the strength of the MVP sample in addressing this issue, as we were able to study reasonable sample sizes of three major populations. Our findings contain a suggestion of some population-specific biology for ERM. Our work has several limitations. ERM is diagnosed reliably via optical coherence tomography⁵² (OCT). Diagnoses recorded in the electronic health record (EHR) may reflect clinical or OCT diagnosis, but with large sample sizes signal overwhelms noise, tending to compensate for diagnosis imprecision. It is a limitation that we relied on EHR-based diagnosis and might have included secondary ERM cases. In relying on chart diagnosis that reflect the skills of a wide range of individual clinicians, it is likely that we included some false-positive amongst the cases with non-ERM pathology. However EHR diagnoses have been used widely and with great success previously for diagnosis of complex genetic traits (such as, for example, major depressive disorder⁵³ and opioid use disorder⁵⁴ specifically in the MVP), and the convergence of the identified risk loci identified with what is known about the pathophysiology of the

disorder, supports that they are likely to be relevant to ERM. A further limitation is the mostly-male composition of the MVP sample; there may be sex-specific risk factors that we could not evaluate.

We identified GWS-significant associations to ERM in EUR, AFR, and AMR each taken individually, and many more GWS-associations in the trans-ancestry meta-analysis. Results from pathway enrichment analyses were consistent with known ERM pathophysiology. Availability of these genomewide results will enable the creation of polygenic risk scores (PRS) expected to be predictive of genetic risk for ERM. These findings should lead to improved understanding of the pathophysiology of ERM and, ideally, identifications of new targets for nonsurgical treatment interventions.

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

Competing Interests Dr. Gelernter is named as an inventor on PCT patent application #15/878,640 entitled: "Genotypeguided dosing of opioid agonists," filed January 24, 2018 and issued on January 26, 2021 as U.S. Patent No. 10,900,082. Dr. Gelernter is paid for editorial work for the journal "Complex Psychiatry" (Karger). Dr. Eliot is ad hoc consultant for Alcon, Dutch Ophthalmic, GelMEDIX, and Genentech; reports research funding from Neurotech and Unity Biotechnology; is a member of the Advisory Board & Stockholder for InGel Therapeutics, Pykus Therapeutics, and RetMap; reports being Advisor, Patents, Royalties, and Stockholder in Aldeyra Therapeutics; and is a member of the Data Safety Monitoring Board (DSMB) for Asclepix Dr. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Bionomics, BioXcel Therapeutics, Boehringer Ingelheim, Clexio, Eisai, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sumitomo Pharma, and Roche/Genentech. Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario. He has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry). He is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America. The other authors all report that they have no competing interests.

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

Acknowledgments This research is based on data from the Million Veteran Program (MVP), Office of Research and Development, Veterans Health Administration, and was supported by the MVP and the Veterans Affairs Cooperative Studies Program study No. 575B. This work was also supported funding from the Department of Veterans Affairs Office of Research and Development grants I01CX001849 - MVP025. D.F.L. was supported by a was supported by an NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation and a Career Development Award CDA-2 from the Veterans Affairs Office of Research and Development (1IK2BX005058-01A2) and is Aimee Mann Fellow of Psychiatric Genetics. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. We also acknowledge the participants and investigators of the FinnGen study. **Author contributions** JG conceived the study, drafted the article, and supervised the work. DL and MG analyzed the data and contributed to drafting the article. HZ and KA contributed to the data analysis. KH contributed to the phenotyping effort in the MVP sample. JG, MBS, and JMG provided administrative support. Additionally, all authors (DL, MG, KH, HZ, KA, JMG, DE, and MBS) reviewed the article and provided critical comments. **Data Availability** Summary statistics will be made available in dbGAP (accession number phs001672) by the Million Veteran Program following publication.

403 REFERENCES

404

Xiao W, Chen X, Yan W, Zhu Z, He M. Prevalence and risk factors of epiretinal membranes: a systematic review and meta-analysis of population-based studies. *BMJ Open*.
 2017;7(9):e014644.

- 408 2. Bianchi L, Altera A, Barone V, et al. Untangling the Extracellular Matrix of Idiopathic Epiretinal
 409 Membrane: A Path Winding among Structure, Interactomics and Translational Medicine. *Cells*.
 410 2022;11(16).
- Fritsche LG, Igl W, Bailey JNC, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. *Nature genetics*. 2016;48(2):134-143.
- 4. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. *Science (New York, N.Y.)*. 2005;308(5720):385-389.
- Xue Z, Yuan J, Chen F, et al. Genome-wide association meta-analysis of 88,250 individuals
 highlights pleiotropic mechanisms of five ocular diseases in UK Biobank. *EBioMedicine*.
 2022;82:104161.
- 419 6. Collins R. What makes UK Biobank special? Lancet. 2012;379(9822):1173-1174.
- Kvale MN, Hesselson S, Hoffmann TJ, et al. Genotyping Informatics and Quality Control for
 100,000 Subjects in the Genetic Epidemiology Research on Adult Health and Aging (GERA)
 Cohort. Genetics. 2015;200(4):1051-1060.
- 423 8. Gelernter J, Sun N, Polimanti R, et al. Genome-wide association study of post-traumatic stress disorder reexperiencing symptoms in >165,000 US veterans. *Nat Neurosci.* 2019;22(9):1394-425 1401.
- 426 9. Klarin D, Damrauer SM, Cho K, et al. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. *Nature genetics*. 2018.
- 428 10. Gaziano JM, Concato J, Brophy M, et al. Million Veteran Program: A mega-biobank to study 429 genetic influences on health and disease. *Journal of clinical epidemiology*. 2016;70:214-223.
- 430 11. Gaziano JM, Concato J, Galea S, Smith NL, Provenzale D. Epidemiologic approaches to veterans' health. *Epidemiologic reviews*. 2015;37:1-6.
- Levey DF, Gelernter J, Polimanti R, et al. Reproducible Genetic Risk Loci for Anxiety: Results From approximately 200,000 Participants in the Million Veteran Program. *Am J Psychiatry*.
 2020;177(3):223-232.
- 435 13. Kurki Ml, Karjalainen J, Palta P, et al. FinnGen: Unique genetic insights from combining isolated population and national health register data. *medRxiv*. 2022:2022.2003.2003.22271360.
- Hunter-Zinck H, Shi Y, Li M, et al. Genotyping Array Design and Data Quality Control in the Million Veteran Program. *American journal of human genetics*. 2020;106(4):535-548.
- Bulik-Sullivan BK, Loh PR, Finucane HK, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature genetics*. 2015;47(3):291-295.
- Luo Y, Li X, Wang X, et al. Estimating heritability and its enrichment in tissue-specific gene sets in admixed populations. *Hum Mol Genet*. 2021;30(16):1521-1534.
- 443 17. Frazer KA, Ballinger DG, Cox DR, et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature*. 2007;449(7164):851-861.
- 447 19. Gharahkhani P, Jorgenson E, Hysi P, et al. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. *Nature communications*.

449 2021;12(1):1258.

- Stein MB, Levey DF, Cheng Z, et al. Genome-wide association analyses of post-traumatic stress disorder and its symptom subdomains in the Million Veteran Program. *Nature genetics*. 2021;53(2):174-184.
- Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran
 Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat*Neurosci. 2021;24(7):954-963.
- LaPierre N, Taraszka K, Huang H, He R, Hormozdiari F, Eskin E. Identifying causal variants by fine mapping across multiple studies. *PLoS genetics*. 2021;17(9):e1009733.
- 458 23. Orozco LD, Chen HH, Cox C, et al. Integration of eQTL and a Single-Cell Atlas in the Human Eye 459 Identifies Causal Genes for Age-Related Macular Degeneration. *Cell reports*. 2020;30(4):1246-460 1259 e1246.
- Gusev A, Ko A, Shi H, et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nature genetics*. 2016;48(3):245-252.
- de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLOS Computational Biology*. 2015;11(4):e1004219.
- Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nature Communications*. 2017;8(1):1826.
- 467 27. Ota A, Tanaka Y, Toyoda F, et al. Relationship between variations in posterior vitreous
 468 detachment and visual prognosis in idiopathic epiretinal membranes. *Clin Ophthalmol.* 469 2016;10:7-11.
- 470 28. Babai N, Sendelbeck A, Regus-Leidig H, et al. Functional Roles of Complexin 3 and Complexin 4 at
 471 Mouse Photoreceptor Ribbon Synapses. *The Journal of neuroscience : the official journal of the*472 *Society for Neuroscience.* 2016;36(25):6651-6667.
- Vaithianathan T, Henry D, Akmentin W, Matthews G. Functional roles of complexin in
 neurotransmitter release at ribbon synapses of mouse retinal bipolar neurons. *The Journal of neuroscience: the official journal of the Society for Neuroscience.* 2015;35(9):4065-4070.
- Jen JC, Chan WM, Bosley TM, et al. Mutations in a human ROBO gene disrupt hindbrain axon pathway crossing and morphogenesis. *Science (New York, N.Y.).* 2004;304(5676):1509-1513.
- 478 31. Gao XR, Huang H, Kim H. Genome-wide association analyses identify 139 loci associated with macular thickness in the UK Biobank cohort. *Human molecular genetics*. 2019;28(7):1162-1172.
- 480 32. Springelkamp H, Mishra A, Hysi PG, et al. Meta-analysis of Genome-Wide Association Studies
 481 Identifies Novel Loci Associated With Optic Disc Morphology. *Genetic epidemiology*.
 482 2015;39(3):207-216.
- 483 33. Liu S, Chen S, Niu T. Genetic association between CDKN2B-AS1 polymorphisms and the 484 susceptibility of primary open-angle glaucoma (POAG): a meta-analysis from 21,775 subjects. *Ir J* 485 *Med Sci.* 2022;191(5):2385-2392.
- 486 34. Vuckovic D, Bao EL, Akbari P, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. *Cell.* 2020;182(5):1214-1231 e1211.
- 488 35. Iglesias Al, Mishra A, Vitart V, et al. Cross-ancestry genome-wide association analysis of corneal thickness strengthens link between complex and Mendelian eye diseases. *Nature* communications. 2018;9(1):1864.
- Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nature genetics*. 2013;45(8):868-876.
- 493 37. Verweij N, van de Vegte YJ, van der Harst P. Genetic study links components of the autonomous nervous system to heart-rate profile during exercise. *Nature communications*. 2018;9(1):898.
- 495 38. Karlsson Linnér R, Biroli P, Kong E, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nature genetics*. 2019;51(2):245-257.

- 498 39. Frank CR, Xiang X, Stagg BC, Ehrlich JR. Longitudinal Associations of Self-reported Vision
 499 Impairment With Symptoms of Anxiety and Depression Among Older Adults in the United
 500 States. *JAMA Ophthalmol.* 2019;137(7):793-800.
- 501 40. Zhao X, Liu W, Lu B, Zhu X, Zhou M, Sun X. Visual impairment and depression in China: a 7-year follow-up study from national longitudinal surveys. *BMJ Open.* 2022;12(4):e055563.
- 503 41. Leduc MS, Niu Z, Bi W, et al. CRIPT exonic deletion and a novel missense mutation in a female 504 with short stature, dysmorphic features, microcephaly, and pigmentary abnormalities. *Am J Med* 505 *Genet A.* 2016;170(8):2206-2211.
- Rossi M, Pellegrini C, Cardelli L, Ciciarelli V, Di Nardo L, Fargnoli MC. Familial Melanoma: Diagnostic and Management Implications. *Dermatol Pract Concept.* 2019;9(1):10-16.
- Tan-Sindhunata MB, Mathijssen IB, Smit M, et al. Identification of a Dutch founder mutation in MUSK causing fetal akinesia deformation sequence. *European journal of human genetics : EJHG.* 2015;23(9):1151-1157.
- Rappu P, Salo AM, Myllyharju J, Heino J. Role of prolyl hydroxylation in the molecular interactions of collagens. *Essays Biochem.* 2019;63(3):325-335.
- Kritzenberger M, Junglas B, Framme C, et al. Different collagen types define two types of idiopathic epiretinal membranes. *Histopathology*. 2011;58(6):953-965.
- Sun C, Zou H, Yang Z, et al. Proteomics and phosphoproteomics analysis of vitreous in idiopathic epiretinal membrane patients. *Proteomics Clin Appl.* 2022;16(5):e2100128.
- 517 47. Song Y, Overmass M, Fan J, et al. Application of Collagen I and IV in Bioengineering Transparent Ocular Tissues. *Frontiers in Surgery*. 2021;8.
- Kim SK. Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. *PloS one*. 2018;13(7):e0200785.
- 521 49. Kichaev G, Bhatia G, Loh PR, et al. Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *American journal of human genetics*. 2019;104(1):65-75.
- 523 50. Nakada C, Satoh S, Tabata Y, Arai K, Watanabe S. Transcriptional repressor foxl1 regulates 524 central nervous system development by suppressing shh expression in zebra fish. *Mol Cell Biol.* 525 2006;26(19):7246-7257.
- 526 51. Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. *Cell.* 2019;177(4):1080.
- 528 52. Do DV, Cho M, Nguyen QD, et al. The impact of optical coherence tomography on surgical decision making in epiretinal membrane and vitreomacular traction. *Trans Am Ophthalmol Soc.* 2006;104:161-166.
- 53. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran
 532 Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. *Nat*533 *Neurosci.* 2021;24(7):954-963.
- 534 54. Zhou H, Rentsch CT, Cheng Z, et al. Association of OPRM1 Functional Coding Variant With Opioid 535 Use Disorder: A Genome-Wide Association Study. *JAMA Psychiatry*. 2020.

Table 1: MVP sample demographic information.

EUR	Case	Control	Total
Male	30176	382566	412742
Age (SEM)	71.15(0.05)	64.22(0.02)	
Female	1198	31486	32684
Age (SEM)	64.78(0.78)	52.10(0.08)	
Total (EUR)	31374	414052	445426
AFR	Case	Control	Total
Male	4398	92592	96990
Age (SEM)	66.63(0.13)	58.66(0.04)	
Female	341	15181	15522
Age (SEM)	59.59(0.51)	48.75(0.09)	
Total (AFR)	4739	107773	112512
AMR	Case	Control	Total
Male	2055	32611	34666
Age (SEM)	68.25(0.20)	55.44(0.09)	
Female	64	3552	3616
Age (SEM)	62.4(0.91)	43.29(0.218)	
Total (AMR)	2119	36163	38282
TOTAL (AII)	38232	<i>557988</i>	596220

Table 2: Independent significant risk loci identified in EUR, AFR, and AMR. A1, risk allele; FREQ, frequency of A1 (sorted by p-value)

EUR ancestry:

Gene	C HR	SNP	BP Hg19/GRCH37	A1	A2	FREQ	ВЕТА	SE	Р
DHX36	3	rs9823832	154024897	С	Т	0.343906	-0.114203	0.00901605	9.06E-37
LPAR1	9	rs6477803	113792417	Т	С	0.80847	-0.117122	0.011001	1.81E-26
CPLX4	1 8	rs7244528	56948972	Α	Т	0.700518	-0.089765	0.00924817	2.84E-22
FOXL1	1 6	rs1019574	86725801	Α	G	0.525586	0.0764702	0.00861526	6.90E-19
CDKN2B-AS1	9	rs10120688	22056499	А	G	0.478935	-0.0759819	0.00858045	8.35E-19
RNU6ATAC21P	6	rs34825161	10185413	Α	G	0.275068	-0.0859338	0.00982183	2.15E-18
ACOXL	2	rs6731210	112270857	Т	С	0.600165	-0.0731687	0.00847459	5.93E-18
ROBO3	1	rs10893291	124705053	G	Α	0.323993	-0.0758934	0.00907502	6.12E-17
PLPP3	1	rs9970807	56965664	Т	С	0.0913253	-0.121161	0.0150691	8.96E-16
ABLIM3	5	rs1011400	148611941	С	G	0.438558	-0.0659999	0.00867952	2.87E-14
HNF1B	7	rs12601991	36101633	Т	G	0.405415	0.0614149	0.00850638	5.21E-13
ACOXL	2	rs114671763	112154449	Т	С	0.0940899	-0.101641	0.0149702	1.13E-11
FTO	1 6	rs17817964	53828066	Т	С	0.393599	0.0569945	0.00857814	3.04E-11
DENND1A	9	rs4838069	126316511	Т	С	0.172974	0.0739937	0.0111857	3.71E-11
RARB	3	rs57281891	25581866	С	СТТ	0.133411	0.0803257	0.0124553	1.13E-10
COL4A4	2	rs6740108	227889559	С	Α	0.414065	-0.0557971	0.00865244	1.13E-10
LPAR1	9	rs1279850	113972498	Α	Т	0.75331	-0.0613734	0.00957904	1.48E-10
TP53	7	rs78378222	7571752	G	Т	0.0119663	0.221799	0.0354849	4.09E-10
FOLH1	1 1	rs10839258	49314465	G	А	0.229578	-0.0635619	0.0101969	4.56E-10
OSTM1	6	rs9480836	108458997	Т	С	0.0729634	0.102286	0.0167332	9.81E-10
SPNS3	7	rs11285864	4354559	Т	TC	0.603578	0.05319	0.00871949	1.06E-09
LPAR1	9	rs5899909	113410155	GAT	G	0.467903	-0.051705	0.00848558	1.11E-09
BCR	2	rs4822369	23516797	Α	С	0.262917	0.0570984	0.00944604	1.50E-09
EPAS1/PRKCE	2	rs4245808	46456486	Α	G	0.656504	0.0531805	0.00885061	1.87E-09
UFL1	6	rs530625467	96875349	G	С	0.0492389	0.145658	0.0252414	7.90E-09
SOX10	2	rs117896793	38381996	Т	G	0.0269773	0.152644	0.0266889	1.07E-08
DPF3	1 4	rs4903064	73279420	С	Т	0.240167	-0.0559642	0.00992863	1.73E-08

CCNI2	5	rs2277066	132072913	С	G	0.0839226	-0.0918094	0.0163619	2.01E-08
DLL1	6	rs7745573	170468193	С	А	0.426806	0.0477801	0.00860443	2.81E-08
EIF3E	8	rs7826090	109288442	G	Α	0.233334	-0.0563344	0.0101514	2.87E-08
HAS2	8	rs279655	122803525	G	А	0.43985	-0.0472866	0.00853638	3.04E-08

AFR ancestry:

Gene	CH R	SNP	BP Hg19/GRCH37	A1	A2	FREQ	ВЕТА	SE	Р
RNU6ATAC21P	6	rs34825161	10185413	А	G	0.130225	-0.210674	0.0374443	1.84088E- 08
NYAP2	2	rs4675026	226889445	Т	С	0.819976	-0.159703	0.0286954	2.61508E- 08
HSPA8	11	rs14686788 7	122932732	Α	С	0.00256511	0.918612	0.165897	3.07234E- 08

AMR ancestry:

Gene	CH R	SNP	BP Hg19/GRCH37	A1	A2	FREQ	BETA	SE	Р
CHRM2	7	rs7801770	136494060	А	G	0.00514367	1.10126	0.184118	2.21E-09
CAMTA1	1	rs150631130	7705819	CGGCA	С	0.00525359	1.13444	0.199554	1.31E-08

<u>Table 3. GWS variants identified in trans-ancestry meta.</u>

555

556557

Bolded variants indicate cases where an identical variant was identified in the EUR only GWAS (15/34).

Gene	CHR	SNP	Position	A1	A2	Freq.	Beta	SE	p-value	Direction (EUR AMR)
DHX36	3	rs28630834	154016838	Α	G	0.6755	0.109	0.0085	2.90E-37	+++
LPAR1	9	rs4978978	113802433	С	G	0.1871	0.1077	0.0101	2.34E-26	+++
CPLX4	18	rs8094635	56948478	Α	G	0.2823	0.0894	0.0086	3.56E-25	+++
RNU6ATAC21P	6	rs34825161	10185413	Α	G	0.2625	-0.0943	0.0093	3.88E-24	
MIR4435-2HG	2	rs200436484	112274727	С	G	0.5843	-0.0793	0.0084	3.35E-21	-?-
FOXL1	16	rs1019574	86725801	Α	G	0.543	0.0713	0.0079	1.18E-19	+++
CDKN2A-AS1	9	rs10811645	22049656	Α	G	0.5195	-0.0695	0.0077	1.90E-19	
ROBO3	11	rs10893291	124705053	Α	G	0.6821	0.0738	0.0083	4.83E-19	+++
PPAP2B	1	rs72664355	57007791	Т	С	0.9176	0.1254	0.0157	1.46E-15	+++
GPR149	3	rs60572329	154085132	CG	С	0.8278	-0.0897	0.0115	6.64E-15	-?+
ABLIM3	5	rs1011400	148611941	С	G	0.4326	-0.0634	0.0084	5.57E-14	-?-
HNF1B	17	rs12601991	36101633	Т	G	0.3906	0.0609	0.0083	2.42E-13	++?
FTO	16	rs17817964	53828066	Т	С	0.3712	0.0586	0.0082	6.56E-13	+++
ARHGEF26- AS1	3	rs7617276	153776826	Т	С	0.6435	0.0587	0.0082	6.86E-13	+++
FOLH1	11	rs2866349	49314336	Т	G	0.7164	0.0633	0.009	2.00E-12	+++
CTXN2	15	rs2413887	48485926	Т	С	0.652	0.1628	0.0232	2.37E-12	?++
ACOXL	2	rs114671763	112154449	Т	С	0.0966	-0.0941	0.0136	4.00E-12	
COL4A4	2	rs13393894	227880543	Α	G	0.5635	0.0529	0.0078	1.46E-11	+++
DENND1A	9	rs4838069	126316511	Т	С	0.1808	0.0725	0.0107	1.48E-11	+?+
DPF3	14	rs4903064	73279420	Т	С	0.7632	0.0611	0.0091	1.98E-11	+++
BCR	22	rs5751598	23514450	Α	G	0.7114	-0.0563	0.0084	2.05E-11	
TP53	17	rs78378222	7571752	Т	G	0.9885	-0.2296	0.0346	3.10E-11	
RARB	3	rs1286767	25592883	Т	С	0.8553	-0.073	0.011	3.16E-11	
OR2K2	9	rs2773533	113980884	Т	С	0.2802	0.0576	0.0087	3.17E-11	+++
FOXL1	16	rs71390846	86714715	С	G	0.1726	0.0687	0.0104	4.09E-11	+++
SPNS3	17	rs12601416	4357773	Α	G	0.4094	-0.0526	0.008	4.33E-11	
LOC646813	11	rs140544819	50366307	Т	С	0.8979	0.0981	0.0151	7.27E-11	+?+
EPAS1/PRKCE	2	rs4245808	46456486	Α	G	0.6642	0.0512	0.0081	2.38E-10	+++
CCNI2	5	rs2277066	132072913	С	G	0.0973	-0.0965	0.0154	3.27E-10	-?-

OR4A5	11	rs11246551	51419389	Т	С	0.1264	-0.0764	0.0124	7.46E-10	
MUSK	9	rs6477779	113392219	Т	С	0.4991	-0.0476	0.0078	1.16E-09	+
OSTM1	6	rs9480836	108458997	Т	С	0.0724	0.0955	0.0157	1.27E-09	+-+
PTPRJ	11	rs7130876	48050995	Α	G	0.7947	0.0592	0.0098	1.34E-09	+++
SOX10	22	rs117896793	38381996	Т	G	0.0265	0.1526	0.0255	2.10E-09	+++
EIF3E	8	rs7826090	109288442	Α	G	0.7644	0.0569	0.0098	6.51E-09	+?+
LIG1	19	rs35844660	48655069	CCT	С	0.4915	-0.0478	0.0083	9.84E-09	-?-
HAS2	8	rs2581482	122801173	Α	G	0.5411	0.0444	0.0078	1.04E-08	+++
COL4A2	13	rs9521744	111054827	Α	Т	0.3752	-0.0462	0.0081	1.16E-08	
DTWD1	15	rs1976551	49923026	С	G	0.7572	0.1352	0.0239	1.45E-08	?++
HNF1B	17	rs34080163	36151146	Α	G	0.1219	0.0646	0.0114	1.52E-08	+++
TRIM48	11	rs113285600	54857903	Т	С	0.8795	0.0695	0.0124	2.15E-08	+++
SH3PXD2A	10	rs56149148	105508171	Т	С	0.1177	0.0652	0.0117	2.54E-08	+++
WWOX	16	rs12928261	79041944	Α	Т	0.5727	-0.0446	0.008	2.74E-08	
SNAP23	15	rs4923947	42791703	Α	G	0.2234	0.1007	0.0182	3.01E-08	+++
TPRX1	19	rs12462705	48304700	Α	G	0.4419	-0.0434	0.0079	3.54E-08	
HAS2	8	rs529279493	122792069	Т	С	0.9949	-0.4191	0.0761	3.59E-08	-??
UFL1	6	rs76152172	96907225	Α	G	0.9477	-0.1158	0.021	3.66E-08	-+-
CDKN2A	9	rs13288666	21973857	Т	С	0.9563	0.1121	0.0204	3.99E-08	++-

Figure 1. Trans-ancestry meta-analysis Manhattan Plot. Lead loci not identified in the European GWAS are highlighted.






Figure 2. eQTL results.

Expression QTLs were investigated in an eye tissue specific database. Lead SNPs were first looked up for each locus, with 2 significant results after multiple testing correction (FDR<0.05): rs4245808 and rs1011400. GWS proxy SNPs were selected when results were not available for the lead SNP, with three additional SNPs showing significant eQTL (FDR<0.05): rs803141, rs2416908, and rs9438. Genotype is on the X axis and Reads Per Kilobase Million (RPKM) is on the Y axis. Scale is variable and relative to the transcript depicted in each figure.



Lead SNP near EPAS1/PRKCE



Three overlapping genes showing eQTL with chr5 lead SNP rs1011400

